NASDAQ:EVLO Evelo Biosciences Q3 2023 Earnings Results & Report Evelo Biosciences beat analyst earnings expectations in its Q3 2023 results, released November 9, 2023. The company reported EPS of -$0.66 versus the -$1.34 consensus estimate. Research:Profile Earnings Announcement Details QuarterQ3 2023Report DateNovember 9, 2023 Evelo Biosciences EPS ResultsActual EPS-$0.66Consensus EPS -$1.34Beat/MissBeat by +$0.68One Year Ago EPSN/AEPS Beat Rate7 of last 8 quartersEvelo Biosciences Revenue ResultsActual RevenueN/AExpected RevenueN/ABeat/MissN/AYoY Revenue GrowthN/AUpcoming EarningsEvelo Biosciences' next earnings date is estimated for Tuesday, November 17, 2026, based on past reporting schedules. Conference Call ResourcesCompany Profile Evelo Biosciences Q3 2023 Earnings FAQ Did Evelo Biosciences beat earnings estimates for Q3 2023? Evelo Biosciences (NASDAQ:EVLO) reported earnings of -$0.66 per share for Q3 2023, beating the consensus estimate of -$1.34. The report was announced on Thursday, November 9, 2023. When is Evelo Biosciences' next earnings date? Evelo Biosciences' next earnings date is estimated for Tuesday, November 17, 2026. MarketBeat tracks confirmed and estimated earnings dates for Evelo Biosciences on the company's earnings history page. Evelo Biosciences Earnings HeadlinesEvelo Biosciences Inc.June 24, 2026 | marketwatch.comEvelo BiosciencesApril 5, 2026 | fool.comElon Musk’s One Stock Retirement PlanJeff Brown picked Nvidia in 2016, before it surged 37,000 percent. Now he's tracking a small AI company he says is the same size Nvidia was a decade ago. The company holds 150 patents protecting its core technology, and Brown believes Elon Musk could soon drive major demand for it. A key catalyst is set for November 11.October 28 at 1:00 AM | Brownstone Research (Ad)Evelo Biosciences (OTC:EVLO) Stock Quotes, Forecast and News SummaryOctober 4, 2024 | benzinga.comEvelo Biosciences (OTC:EVLO) Stock, Insider Trading ActivityOctober 4, 2024 | benzinga.comEVLO Expands Portfolio with Launch of EVLO SYNERGY - A High-Density 5 MWh Battery Storage SolutionAugust 30, 2024 | ca.finance.yahoo.comSee More Evelo Biosciences Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Evelo Biosciences? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Evelo Biosciences and other key companies, straight to your email. Email Address About Evelo BiosciencesEvelo Biosciences (NASDAQ:EVLO) was a clinical-stage biotechnology company focused on developing orally administered medicines designed to act on the small intestine and influence systemic immune responses. Its approach, known as the SINTAX platform, was intended to use selected microbes or microbial-derived signals to modulate immune activity without requiring traditional systemic drug delivery. The company’s development programs targeted inflammatory and immune-mediated diseases, as well as oncology indications. Its lead candidates included EDP1815, an investigational therapy studied in conditions such as psoriasis and atopic dermatitis, and EDP2939, an investigational program designed to stimulate immune responses for potential use in cancer treatment. Evelo was headquartered in Cambridge, Massachusetts, and conducted clinical development activities through research and trial networks in the United States and other regions. In 2023, the company announced that it was discontinuing clinical development activities, reducing its workforce and evaluating strategic alternatives. As a result, Evelo Biosciences is best understood as a former clinical-stage biotechnology company rather than an active developer with a broad commercial product portfolio.View Evelo Biosciences ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles Heavy Metal: Why Nucor Could Be an Overlooked AI Infrastructure WinnerThe Invisible AI Backbone: Corning's AI Fiber PlayWhy Tesla’s Upside Is About More Than a SpaceX MergerPalantir's Q3 Bar Is Higher Than It Looks: 3 Numbers to WatchAmkor's Mobile Business Is Slowing, But Its AI Ambitions Aren'tSherwin-Williams Remains Evergreen in a Frozen Housing MarketTaiwan Semiconductor Flexes Pricing Power on AI's Frontline Upcoming Earnings Amazon.com (10/29/2026)Starbucks (10/29/2026)Anheuser-Busch InBev SA/NV (10/29/2026)Mondelez International (10/29/2026)Altria Group (10/29/2026)Enterprise Products Partners (10/29/2026)Cheniere Energy (10/29/2026)Shell (10/29/2026)TotalEnergies (10/29/2026)Arthur J. Gallagher & Co. (10/29/2026) Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
